BiovaxID NHL Vaccine Phase 3 Trial to Stop
Biovest International, Inc. BVTI, a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. ABPI, on April 24 announced that its Chairman and CEO, Dr. Steven Arikian, is scheduled for numerous media interviews regarding the next steps for its cancer vaccine breaktrhough, BiovaxID.
Dr. Arikian commented, "Based on our recent news, it is not surprising that we are being asked to participate in media interviews and present at key investor events. I believe it is fair to say that BiovaxID is on track to potentially become the first ever cancer vaccine approved in the U.S. and/or Europe, initially targeting the treatment of non-Hodgkin's lymphoma (NHL), an insidious and often fatal cancer. The independent Data Monitoring Committee (DMC) just last week recommended stopping our Phase 3 clinical trial early and unblinding the results. The DMC has offered to meet with the FDA to assist in presenting the data and discussing accelerated and/or conditional approval. We are in the process of unblinding the results at this time. In addition to NHL, we believe the vaccine is capable of treating other forms of B-cell malignancy, covering many kinds of cancers."
@ltaLINK to This SOURCE
"Consider What's Important, Not Just What's Urgent"